Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel Free CDTTW Stock Alerts

Conduit Pharmaceuticals (CDTTW) Competitors

$0.01 0.00 (-4.69%)
As of 03:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

CDTTW vs. SXTPW, BFRIW, CINGW, CLVR, and CMRAW

Should you buy Conduit Pharmaceuticals stock or one of its competitors? Conduit Pharmaceuticals's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Clever Leaves (CLVR), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Conduit Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

Conduit Pharmaceuticals (NASDAQ:CDTTW) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Company Net Margins Return on Equity Return on Assets
Conduit PharmaceuticalsN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conduit PharmaceuticalsN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

In the previous week, Conduit Pharmaceuticals and Conduit Pharmaceuticals both had 1 articles in the media. Conduit Pharmaceuticals' average media sentiment score of 0.00 equaled 60 Degrees Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Conduit Pharmaceuticals Neutral
60 Degrees Pharmaceuticals Neutral

Summary

60 Degrees Pharmaceuticals beats Conduit Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

In the previous week, Biofrontera and Biofrontera both had 1 articles in the media. Biofrontera's average media sentiment score of 0.00 equaled Conduit Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Biofrontera Neutral
Conduit Pharmaceuticals Neutral

Summary

Biofrontera beats Conduit Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Cingulate?

Conduit Pharmaceuticals (NASDAQ:CDTTW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

In the previous week, Conduit Pharmaceuticals and Conduit Pharmaceuticals both had 1 articles in the media. Conduit Pharmaceuticals' average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score.

Company Overall Sentiment
Conduit Pharmaceuticals Neutral
Cingulate Neutral

Company Net Margins Return on Equity Return on Assets
Conduit PharmaceuticalsN/A N/A N/A
Cingulate N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conduit PharmaceuticalsN/AN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Summary

Conduit Pharmaceuticals and Cingulate tied by winning 0 of the 0 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Clever Leaves?

Conduit Pharmaceuticals (NASDAQ:CDTTW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Conduit Pharmaceuticals has higher earnings, but lower revenue than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conduit PharmaceuticalsN/AN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Conduit Pharmaceuticals had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for Conduit Pharmaceuticals and 0 mentions for Clever Leaves. Conduit Pharmaceuticals' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Conduit Pharmaceuticals Neutral
Clever Leaves Neutral

Company Net Margins Return on Equity Return on Assets
Conduit PharmaceuticalsN/A N/A N/A
Clever Leaves N/A N/A N/A

Summary

Clever Leaves beats Conduit Pharmaceuticals on 3 of the 4 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Comera Life Sciences?

Conduit Pharmaceuticals (NASDAQ:CDTTW) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Company Net Margins Return on Equity Return on Assets
Conduit PharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conduit PharmaceuticalsN/AN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

In the previous week, Conduit Pharmaceuticals had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Conduit Pharmaceuticals and 0 mentions for Comera Life Sciences. Conduit Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Conduit Pharmaceuticals Neutral
Comera Life Sciences Neutral

Summary

Conduit Pharmaceuticals and Comera Life Sciences tied by winning 1 of the 2 factors compared between the two stocks.

Get Conduit Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDTTW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDTTW vs. The Competition

Export
MetricConduit PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.50B$7.26B$13.10B
Dividend YieldN/A2.63%2.52%12.57%
P/E RatioN/A792.39274.6925.75
Price / SalesN/A850.84679.2597.61
Price / CashN/A88.6477.8052.76
Price / BookN/A10.6910.526.34
Net IncomeN/A$2.83B$3.49B$360.00M
7 Day PerformanceN/A-0.69%-1.08%-0.10%
1 Month PerformanceN/A-1.10%-3.39%-3.41%
1 Year PerformanceN/A2.10%15.08%5.46%

Conduit Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CDTTW
Conduit Pharmaceuticals
N/A$0.01
-4.7%		N/A+0.0%$0.00N/AN/A7
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
flat		N/A-25.4%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.02
+1.5%		N/A-80.2%$0.00$46.18MN/A70
CINGW
Cingulate
N/A$0.01
-7.9%		N/A-85.3%$0.00N/AN/A20
CLVR
Clever Leaves
N/A$0.00
flat		N/A-50.0%$0.00$17.42MN/A560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CDTTW) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel